Effect of Bacterial Vaginosis on HIV Susceptibility and Female Genital Immunology

Effect of Bacterial Vaginosis and Its Treatment on HIV Susceptibility and Female Genital Immunology

A non-randomized, interventional, longitudinal clinical study to quantify the impact of bacterial vaginosis treatment on HIV susceptibility and genital immunology in Kenyan women.

Study Overview

• Status: Completed
• Conditions: HIV Infections; Bacterial Vaginosis
• Intervention / Treatment: Drug: Metronidazole

Detailed Description

Bacterial Vaginosis (BV), defined as an alteration in the normal vaginal bacteria ("microbiome"), is characterized by a reduction of hydrogen peroxide-producing gram-positive lactobacilli and overgrowth of gram-negative and anaerobic bacteria. BV is more prevalent in SSA and usually recurs soon after treatment. BV is associated with vaginal inflammation, an increased HIV acquisition risk among uninfected women, and increased HIV transmission to the male sexual partner of a co-infected woman. Therefore, BV may be responsible for up to 17% of HIV transmission events in SSA.

There are several hypotheses for the mechanisms by which BV may increase the risk of HIV acquisition. These include the disruption of mucosal barrier, alteration of protective innate immunity, and increased number and/or susceptibility of HIV target cells in the genital mucosa. Longitudinal studies that address the mechanisms by which the vaginal microbiota alters host mucosal immunology and HIV risk will help us better understand the impact of BV and it's treatment on mucosal immunology and HIV susceptibility. The goal of this non-randomized, interventional, longitudinal clinical study is to use a novel ex vivo HIV infectivity assay developed in the Kaul lab to quantify the effect of BV and its treatment on HIV susceptibility and genital immunology in HIV-uninfected women from Nairobi, Kenya. Fifty HIV, STI-uninfected women with bacterial vaginosis on Nugent scoring will be provided with one week of metronidazole 400mg po three times daily (as per Kenyan National Guidelines). Cytobrush and vaginal SoftCup sampling will be performed at baseline and 4 weeks after treatment initiation, at the same stage of the menstrual cycle. The primary endpoint will be pseudovirus entry into cervix-derived CD4+ T cells. Secondary endpoints will include a pre-defined cervico-vaginal inflammation score; genital CD4+ T cell immune characteristics; the genital microbiome; the genital proteome.

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Phase 1

Contacts and Locations

Study Locations

• Kenya
  • Nairobi, Kenya
    • Kenya AIDS Vaccine Initiative Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 49 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Participants are over 18 years of age, not pregnant and willing to give informed consent, and answer short questionnaires on economic status, and sexual risk behavior.
2. Willing to comply with the requirements of the protocol
3. HIV and classical STI (see below) negative
4. test positive for BV, defined as Nugent score from 7-10
5. willing to take oral metronidazole twice a day for 7 days
6. willing to abstain from alcohol during and for 48 hours after metronidazole treatment

Exclusion Criteria:

1. HIV infected
2. Deemed by physician to be unlikely to complete study protocol.
3. Pregnant.
4. Irregular menstrual cycle, or actively menstruating at the time of genital sampling.
5. Tested positive for classical STIs or having genital ulcers
6. Prior hysterectomy
7. Contraindication, allergy or intolerance to use of metronidazole

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: metronidazole; 50 women who test negative for HIV and classical sexually transmitted infections but test positive for Bacterial Vaginosis will be treated with metronidazole at a dosage of 400mg/dose, 3 doses per day, for 7 days (as per Kenyan National Guidelines).	Drug: Metronidazole; Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.; Other Names: flagyl

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent HIV pseudovirus entry into cervical CD4+ T cells.	The percentage of cervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct will be quantified by flow cytometry.	up to 8 months
Total number of cervical CD4+ T cells infected ex vivo with HIV.	The total number of cervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct will be quantified by flow cytometry.	up to 8 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
A genital inflammation score based on genital levels of pro-inflammatory cytokines and chemokines.	Level of 14 genital cytokines/chemokines (GM-CSF, IL-1a, IL-8, MCP-1, MIG, MIP-3a, RANTES, IL-10, IL-17, IL-1b, IL-6, IP-10, MIP-1b, TNF-a) will be combined into a genital inflammation score [Arnold K et al, Muc Immunol, 2015].	up to 8 months
The cervico-vaginal microbiome.	The cervico-vaginal microbiome will be assessed by 16s rRNA sequencing before and after metronidazole therapy.	up to 8 months
Genital proteome analysis.	The genital proteome will be assessed by mass spectroscopy before and after metronidazole therapy.	up to 8 months
CD4+ expression of pre-defined HIV susceptibility markers	Surface expression of CCR5, CD69, a4b7 and a4b1 by endocervical CD4 T cells before and after metronidazole therapy.	up to 8 months

Collaborators and Investigators

• Sponsor: University of Toronto

Study record dates

Study Major Dates

• Study Start: August 1, 2015
• Primary Completion (Actual): November 1, 2015
• Study Completion (Actual): November 1, 2015

Study Registration Dates

• First Submitted: August 14, 2015
• First Submitted That Met QC Criteria: August 17, 2015
• First Posted (Estimate): August 19, 2015

Study Record Updates

• Last Update Posted (Estimate): February 10, 2016
• Last Update Submitted That Met QC Criteria: February 9, 2016
• Last Verified: February 1, 2016

More Information

Terms related to this study

• Keywords: Microbiome; Bacterial vaginosis; Genital immunology; HIV susceptibility; Virus entry assay
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Disease Attributes; Bacterial Infections; Bacterial Infections and Mycoses; Vaginitis; Disease Susceptibility; Vaginal Diseases; Vaginosis, Bacterial; Anti-Infective Agents; Anti-Bacterial Agents; Antiprotozoal Agents; Antiparasitic Agents; Metronidazole
• Other Study ID Numbers: UTorontoBV